Form 4: Alkermes Director Richard Gaynor Reports Equity Transactions

Alkermes plc Director Richard Gaynor reported the acquisition of stock options and restricted stock units, alongside the vesting and subsequent sale of shares for tax purposes.

Summary

• Richard Gaynor, a Director of Alkermes plc, reported several equity transactions.
• On May 20, 2026, Gaynor was granted 11,538 Non-Qualified Stock Options with an exercise price of $36.98, vesting in full on May 20, 2027, and expiring on May 20, 2036.
• On May 20, 2026, Gaynor also received 5,409 Restricted Stock Unit Awards, which vest in full on May 20, 2027.
• On May 21, 2026, 6,142 Restricted Stock Units vested and were converted into Ordinary Shares.
• Concurrently, 1,475 Ordinary Shares were disposed of at $36.95 per share, likely to cover tax obligations related to the RSU vesting.
• Following these transactions, Gaynor directly beneficially owns 35,751 Ordinary Shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, reflecting ongoing director alignment through new equity grants and the routine processing of vested awards. The tax-related sale is a common occurrence and does not detract significantly from the overall positive signal of continued insider ownership and incentive alignment.

Positives

• Director Richard Gaynor was granted 11,538 Non-Qualified Stock Options, indicating continued alignment with shareholder interests.
• Gaynor also received 5,409 Restricted Stock Unit Awards, further aligning his incentives with the company's long-term performance.
• The vesting of 6,142 Restricted Stock Units demonstrates the realization of previously granted equity compensation.

Negatives

• 1,475 Ordinary Shares were disposed of at $36.95, likely for tax withholding purposes, reducing direct share ownership.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance, but the grant of new equity awards to a director suggests ongoing commitment to long-term incentives.

Industry Context

StockSavvy.ai notes that equity grants to directors, such as stock options and restricted stock units, are standard practice across the pharmaceutical and biotechnology industries. These grants are designed to align the interests of company leadership with long-term shareholder value creation, a common strategy for executive retention and motivation in competitive sectors.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of equity compensation, including the mix of stock options and restricted stock units with multi-year vesting schedules, is consistent with compensation practices seen in comparable biopharmaceutical companies.
• For instance, companies like Biogen Inc. or Gilead Sciences Inc. frequently utilize similar equity-based incentives for their executive and board members to foster long-term commitment and performance alignment.

Related Party Transactions

• The reported transactions are related party transactions by definition, involving a director's equity compensation and share ownership. No other related party dealings are disclosed in this filing.

Stakeholder Impact

• Shareholders: The grant of new equity awards to a director aligns management's interests with long-term shareholder value. The sale of shares for tax purposes is a common event and has minimal impact on overall share structure.
• Employees: No direct impact on employees is indicated by this filing.
• Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• The newly granted Non Qualified Stock Options and Restricted Stock Unit Awards will vest in full on May 20, 2027.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation grants and a tax-related sale by a director. While the new grants align the director's interests with the company's long-term performance, the transactions themselves are not indicative of a fundamental change in the company's prospects or valuation. Therefore, a 'hold' recommendation is appropriate, as the filing provides no new information to warrant a change in investment thesis.

Keywords

Alkermes plc, ALKS, Richard Gaynor, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Director Transactions, Share Ownership